Interview with Petr Tor, Country Director, Stallergenes Czech Republic
Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did…
Satisfying diverse healthcare needs around the world.
Around the world there are still many diseases for which no effective treatments exist and many patients who do not have adequate access to the medicines they need. As a global pharmaceutical company addressing these unmet medical needs, Eisai is committed to making contribution to better healthcare for patients and their families around the world through its business activities.
We place primary emphasis on patients and their families, we strive to increase the benefits that health care provides them and we conduct our business to meet their diversified health care needs worldwide. We aim to be Human Health Care companies that make a meaningful contribution under any health care system through our business activities around the world.
Contact
Eisai GesmbH, organizační složka
Holušická 2253/1 Praha 4, 14800 Czech Republic
t: +420 242 485 839 f: +420 242 485 840
www.eisai.at
Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did…
Mr. Pfannenschmidt, you have been working for Boehringer Ingelheim for three decades, outlasting several company chairman and witnessing the birth and evolution of the corporate vision “Value through Innovation”. Before…
Mr. Bruzl, we often interview pharmaceutical managers that studied medicine, pharmaceutical science, or business—we do not interview many managers that have a background in law. How did you find yourself…
Infirmary and ultimately leading to a position heading the Czech Republic and Slovakian organization for Janssen. Can you begin by introducing yourself to our readers and giving them an overview…
The Czech Republic is home to Apotex’s oldest branch within a Europe, established in 1992. You yourself joined the organization in 1993. What has been this company’s growth trajectory in…
Mr. Bartoš, you are celebrating your 15th anniversary with Merck this year, and your international career has offered you the opportunity to work throughout Europe. Over these years, how have…
Mr. Pospíšil, you have quite an interesting background, with a degree in agricultural economy engineering. You eventually left the field in 1991 to consult for Lundbeck, building the business here.…
Mr. Gyürüsi, Gedeon Richter is a 111-year-old company that is synonymous with the Central and Eastern European pharma industry. The business has been present in Czechoslovakia since 1956, and has…
Dr. Janda, can you please begin by introducing our readers to the ACRO-CZ, and explicate its mission on this market? Mimicking the European standards, we also wanted to connect all…
Dr. Zörner, can you please begin by introducing our readers to the CAFF (Czech Association of Pharmaceutical Firms), and explicate its key activities and mission? We represent 24 companies in…
Mr. Březovký, can you begin with an introduction to SUKL and its role within the Czech Republic’s complex regulatory environment? I would like to begin by noting that I have…
In the Czech Republic, homeopathic medicines were prohibited during the communistic period, but found resurgence after 1989. Can you give us an overview of the development of this form of…
See our Cookie Privacy Policy Here
